

USSN 09/677,822  
Page 2

**LISTING OF CLAIMS:**

The following is a marked-up version of the Claims, provided pursuant to 37 C.F.R. §1.121 (c)(1)(ii) with instructions and markings showing changes made herein to the previous version of the Claims on record. Underlining denotes added text while strikeout denotes deleted text.

Claims 1-33. (Cancelled)

34. (Previously Presented) A variant of a polypeptide of interest comprising a T-cell epitope, wherein said variant differs from said polypeptide of interest by having an altered T-cell epitope such that said variant produces an immunogenic response in an individual which is greater than the immunogenic response produced by said polypeptide of interest, wherein said T-cell epitope of said polypeptide of interest is altered to produce said variant, and wherein said T-cell epitope is altered by having a terminal portion of said polypeptide of interest comprising said T-cell epitope replaced with a corresponding terminal portion of a homolog of said polypeptide of interest wherein said homolog does not comprise a T-cell epitope identical to said replaced T-cell epitope.

35. (Previously Presented) The variant of Claim 34, wherein said polypeptide of interest is not recognized by said individual as endogenous to said individual.

36. (Previously Presented) The variant of Claim 34, wherein said T-cell epitope is altered with amino acid substitutions.

37. (Previously Presented) A variant of a polypeptide of interest comprising at least one T-cell epitope, wherein said variant differs from said polypeptide of interest by having at least one altered T-cell epitope, such that said variant produces an immunogenic response in an individual which is greater than the immunogenic response produced by said polypeptide of interest, wherein said at least one T-cell epitope of said polypeptide of interest is altered to produce said variant, and wherein said T-cell epitope is altered by having a terminal portion of said polypeptide of interest comprising said T-cell epitope replaced with a corresponding

GC527C2 Resp to Final Office Action 11-4-04

USSN 09/677,822  
Page 3

terminal portion of a homolog of said polypeptide of interest wherein said homolog does not comprise a T-cell epitope identical to said replaced T-cell epitope.

38. (Previously Presented) The variant of Claim 37, wherein said polypeptide of interest is not recognized by said individual as endogenous to said individual.

39. (Previously Presented) The variant of Claim 37, wherein said T-cell epitope is altered with amino acid substitutions.